Tower Research Capital (TRC)’s Ascentage Pharma AAPG Stock Holding History

Tower Research Capital (TRC)’s Portfolio AAPG Stock Details AAPG Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$12.4K	Buy	518 +288	+125%	+$7.09K	﹤0.01%	3794
2025 Q4	$6.04K	Sell	230 -599	-72%	-$19.6K	﹤0.01%	4084
2025 Q3	$32.4K	Buy	+829	New	+$33.6K	﹤0.01%	2877

Other funds holding AAPG

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

XY Capital Central, Hong Kong $101M AUM 1.14% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

EWA

EverSource Wealth Advisors Birmingham, Alabama $2.97B AUM 28.72% 1-Year Est. Return

Tower Research Capital (TRC)'s AAPG Position: Q1 2026 in Review

Tower Research Capital (TRC) increased its Ascentage Pharma (AAPG) stake by 125% in Q1 2026, buying an estimated $7.09K and bringing the position to 518 shares worth $12.4K. The position accounts for ﹤0.01% of the portfolio, ranked #3794.

Tower Research Capital (TRC) first reported a position in AAPG in Q3 2025 and has held it in 3 quarters since. The position peaked at $32.4K in Q3 2025. 7 funds tracked by Wall St. Rank hold AAPG as of Q1 2026.

Tower Research Capital (TRC) held 518 shares of Ascentage Pharma worth $12.4K as of Q1 2026.
Tower Research Capital (TRC) bought 288 Ascentage Pharma shares in Q1 2026, an estimated $7.09K.
Ascentage Pharma made up ﹤0.01% of Tower Research Capital (TRC)'s portfolio in Q1 2026, its #3794 holding.
Tower Research Capital (TRC) first reported a position in Ascentage Pharma in Q3 2025 and has held it in 3 quarters since.
Tower Research Capital (TRC)'s Ascentage Pharma position peaked at $32.4K in Q3 2025.
7 funds tracked by Wall St. Rank held Ascentage Pharma as of Q1 2026.

Based on Tower Research Capital (TRC)'s 13F filing for Q1 2026, filed 15 May 2026.